Form 8-K - Current report:
SEC Accession No. 0001372514-25-000014
Filing Date
2025-03-25
Accepted
2025-03-25 07:00:31
Documents
14
Period of Report
2025-03-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kprx-20250325.htm   iXBRL 8-K 25768
2 EX-99.1 ex991-pressreleasedecember.htm EX-99.1 95983
  Complete submission text file 0001372514-25-000014.txt   259709

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kprx-20250325.xsd EX-101.SCH 1800
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kprx-20250325_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kprx-20250325_pre.xml EX-101.PRE 13058
16 EXTRACTED XBRL INSTANCE DOCUMENT kprx-20250325_htm.xml XML 2814
Mailing Address 332 ENCINITAS BOULEVARD SUITE 102 ENCINITAS CA 92024
Business Address 332 ENCINITAS BOULEVARD SUITE 102 ENCINITAS CA 92024 781-788-8869
KIORA PHARMACEUTICALS INC (Filer) CIK: 0001372514 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36672 | Film No.: 25765798
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)